journal article·2024-11Open access

Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer

Yu‐Chuan Lin, Mei‐Chih Chen, Shi‐Wei Huang, Yeh Chen, Jennifer Hui‐Chun Ho, Fang‐Yu Lin, Xiao‐Tong Tan, Hung‐Che Chiang, Chiu‐Ching Huang, Chih‑Yen Tu, Der‐Yang Cho, Shao‐Chih Chiu

Advanced Science· Volume 11· Issue 41

Abstract

Abstract Immunotherapy targeting immune checkpoints (ICPs), such as programmed death‐ligand‐1 (PD‐L1), is used as a treatment option for advanced or metastatic non‐small cell lung cancer (NSCLC). However, overall response rate to anti‐PD‐L1 treatment is limited due to antigen heterogeneity and the immune‐suppressive tumor microenvironment. Human leukocyte antigen‐G (HLA‐G), an ICP as well as a neoexpressed tumor‐associated antigen, is previously demonstrated to be a beneficial target in combination with anti‐PD‐L1. In this study, a nanobody‐based trispecific T cell engager (Nb‐TriTE) is developed, capable of simultaneously binding to T cells, macrophages, and cancer cells while redirecting T cells toward tumor cells expressing PD‐L1‐ and/or HLA‐G. Nb‐TriTE shows broad spectrum anti‐tumor effects in vitro by augmenting cytotoxicity mediated by human peripheral blood mononuclear cells (PBMCs). In a humanized immunodeficient murine NSCLC model, Nb‐TriTE exhibits superior anti‐cancer potency compared to monoclonal antibodies and bispecific T cell engagers. Nb‐TriTE, at the dose with pharmacoactivity, does not induce additional enhancement of circulating cytokines secretion from PMBCs. Nb‐TriTE effectively prolongs the survival of mice without obvious adverse events. In conclusion, this study introduces an innovative therapeutic approach to address the challenges of immunotherapy and the tumor microenvironment in NSCLC through utilizing the dual ICP‐targeting Nb‐TriTE.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · CAR-T cell therapy research · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Translational Cell Therapy Center China Medical University Hospital No. 2, Yude Rd., North Dist. Taichung City 404 Taiwan

Shine‐On BioMedical Co. Ltd. Rm. B, 10F., No. 573, Sec. 2, Taiwan Blvd., West Dist. Taichung City 403 Taiwan

Institute of New Drug Development China Medical University Taichung City 404 Taiwan

Institute of Biomedical Sciences National Chung Hsing University Taichung City 402 Taiwan

Department of Food Science and Biotechnology National Chung Hsing University Taichung City 402 Taiwan

Center for Translational Genomics and Regenerative Medicine Research China Medical University Hospital Taichung City 404 Taiwan

Department of Ophthalmology China Medical University Hospital China Medical University Taichung City 404 Taiwan

Department of Medical Research Eye Center China Medical University Hospital Taichung City 404 Taiwan

College of Medicine China Medical University Taichung City 404 Taiwan

Division of Nephrology and the Kidney Institute Department of Internal Medicine China Medical University Hospital Taichung City 404 Taiwan

Division of Pulmonary and Critical Care Department of Internal Medicine China Medical University Hospital Taichung City 404 Taiwan

School of Medicine College of Medicine China Medical University Taichung City 404 Taiwan

Drug Development Center China Medical University Taichung City 404 Taiwan

Department of Neurosurgery China Medical University Hospital Taichung City 404 Taiwan

Funding

China Medical University Hospital

References (49)

Show source-provided references
1. Thandra K. C. · Contemp Oncol · 2021 · 25 · 45
2. 10.1016/j.suronc.2021.10167410.1016/j.suronc.2021.101674 ↗
3. 10.1016/S1470-2045(14)71180-510.1016/S1470-2045(14)71180-5 ↗
4. 10.1002/jssc.20190073610.1002/jssc.201900736 ↗
5. 10.1002/jcp.2937110.1002/jcp.29371 ↗
6. 10.1634/theoncologist.2014-042210.1634/theoncologist.2014-0422 ↗
7. 10.3389/fonc.2018.0031510.3389/fonc.2018.00315 ↗
8. 10.1007/s00018-020-03459-110.1007/s00018-020-03459-1 ↗
9. 10.1007/s40262-019-00804-x10.1007/s40262-019-00804-x ↗
10. 10.1002/cam4.341010.1002/cam4.3410 ↗
11. 10.1016/bs.acr.2019.03.00210.1016/bs.acr.2019.03.002 ↗
12. 10.1634/theoncologist.2019-IO-S1-s0510.1634/theoncologist.2019-IO-S1-s05 ↗
13. 10.1093/annonc/mdz11310.1093/annonc/mdz113 ↗
14. 10.1158/2326-6066.CIR-15-009710.1158/2326-6066.CIR-15-0097 ↗
15. 10.1038/ncomms1050110.1038/ncomms10501 ↗
16. 10.1016/j.tcb.2019.07.00210.1016/j.tcb.2019.07.002 ↗
17. 10.1371/journal.pone.003067610.1371/journal.pone.0030676 ↗
18. 10.3389/fimmu.2020.0168510.3389/fimmu.2020.01685 ↗
19. 10.1111/cas.1580610.1111/cas.15806 ↗
20. 10.1158/0008-5472.CAN-15-108210.1158/0008-5472.CAN-15-1082 ↗
21. 10.1038/nature1395410.1038/nature13954 ↗
22. 10.1126/scitranslmed.aad711810.1126/scitranslmed.aad7118 ↗
23. 10.1186/s13148-021-01221-310.1186/s13148-021-01221-3 ↗
24. 10.1158/0008-5472.CAN-15-025510.1158/0008-5472.CAN-15-0255 ↗
25. 10.1186/s13045-023-01482-w10.1186/s13045-023-01482-w ↗
26. 10.1073/pnas.92.15.702110.1073/pnas.92.15.7021 ↗
27. 10.1200/JCO.2015.64.997010.1200/JCO.2015.64.9970 ↗
28. 10.1182/blood.V95.6.209810.1182/blood.V95.6.2098 ↗
29. 10.1038/s41571-020-0347-510.1038/s41571-020-0347-5 ↗
30. 10.2217/imt-2020-025610.2217/imt-2020-0256 ↗
31. 10.1158/1078-0432.CCR-20-284510.1158/1078-0432.CCR-20-2845 ↗
32. 10.1186/s13046-019-1354-110.1186/s13046-019-1354-1 ↗
33. 10.1126/scitranslmed.aal429110.1126/scitranslmed.aal4291 ↗
34. 10.1186/s40364-021-00294-910.1186/s40364-021-00294-9 ↗
35. 10.1038/s42003-021-01790-210.1038/s42003-021-01790-2 ↗
36. 10.1016/j.pharmthera.2017.08.00510.1016/j.pharmthera.2017.08.005 ↗
37. 10.1186/s13046-022-02474-310.1186/s13046-022-02474-3 ↗
38. 10.1136/jitc-2021-00305010.1136/jitc-2021-003050 ↗
39. 10.1002/advs.20220685610.1002/advs.202206856 ↗
40. 10.3389/fimmu.2018.0174010.3389/fimmu.2018.01740 ↗
41. 10.1146/annurev-med-062315-12024510.1146/annurev-med-062315-120245 ↗
42. 10.1111/tan.1242710.1111/tan.12427 ↗
43. 10.1038/bjc.2017.35610.1038/bjc.2017.356 ↗
44. 10.1016/j.ejps.2014.11.00510.1016/j.ejps.2014.11.005 ↗
45. 10.1038/s41577-021-00547-610.1038/s41577-021-00547-6 ↗
46. 10.3390/cancers1510282410.3390/cancers15102824 ↗
47. 10.21873/anticanres.1156410.21873/anticanres.11564 ↗
48. 10.1016/j.lungcan.2016.05.00710.1016/j.lungcan.2016.05.007 ↗
49. 10.1038/s41598-017-03677-x10.1038/s41598-017-03677-x ↗